A research group at Washington University School of Medicine has released animal data showing restriction of tumor growth with a novel mRNA therapeutic delivered in nanoparticles based on Altamira Therapeutics Ltd.’s Semaphore delivery platform.
The role that mitochondrial inner membrane protein (IMMT) has in regards to clinicopathology and tumor microenvironment in breast cancer in unclear. IMMT is part of the mitochondrial contact site and cristae organizing system (MICOS) and its function is to maintain mitochondrial integrity.
CSPC Megalith Biopharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a humanized monoclonal antibody targeting nectin-4 covalently linked to cytotoxic agents through a linker. They are reported to be useful for the treatment of cancer.
Impact Therapeutics (Shanghai) Inc. has divulged substituted tricyclic compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors reported to be useful for the treatment of cancer.
T cells do not have the last word in some breast cancers. According to a study from the University of Pittsburgh, the key to estrogen receptor positive (ER+) breast tumors are macrophages, not T cells, and targeting them could prevent immunotherapy failure in this type of cancer.
In the March 2023 issue of Science Immunology, researchers working at the City of Hope National Medical Center reported on the discovery the mechanisms by which the spliced X-box–binding protein 1 (XBP1s) served essential functions in the IL-15-dependent survival of natural killer (NK) cells. Since XBP1s is known to play critical roles in MHCII expression, the unfolded protein stress response, and ultimately tumorigenesis, the study provided deep insights into the understanding of NK cell biology with translational potential.
Previous studies have implicated OBSCN in breast tumorigenesis and have also demonstrated that low OBSCN levels correlate with significantly reduced overall and relapse-free survival in breast cancer patients. In a recent study, researchers from Memorial Sloan Kettering Cancer Center aimed to investigate the mechanisms involved in the regulation of OBSCN.
